Valuation: Simulations Plus, Inc.

Market Cap 369M 323M 300M 276M 519M 35.6B 528M 3.57B 1.4B 17.4B 1.38B 1.35B 60.13B P/E 2026 *
43.4x
P/E 2027 * 39.8x
Enterprise Value 369M 323M 300M 276M 519M 35.6B 528M 3.57B 1.4B 17.4B 1.38B 1.35B 60.13B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 4.27x
Free-Float
82.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week+0.16%
Current month-0.33%
1 month+0.05%
3 months+19.20%
6 months-10.67%
Current year+0.11%
1 week 18.19
Extreme 18.19
18.29
1 month 18.14
Extreme 18.14
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.87
Extreme 7.87
90.92
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Director/Board Member 58 2014-12-02
Chairman 76 2024-12-16
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell

Executive/Senior Manager

-1,000 0.0050%
7/1/26 Sell

Founder

-4,177 0.0207%
6/16/26 Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+0.16%+38.89%-62.07% 369M
-2.48%-4.42%-34.32%-7.59% 30.74B
-3.66%-10.98%-46.05%+160.83% 13.18B
+1.12%-4.56%-24.32%+57.50% 5.35B
-4.76%-4.94% - - 2.19B
-2.32%-11.06%+45.77%-35.33% 1.9B
-3.41%-2.18% - - 1.84B
-4.20%-6.07%+37.90%+99.54% 893M
-2.10%-3.55%-42.81%-56.65% 762M
-4.79%-10.02%-42.93%-82.15% 658M
Average -2.65%-3.89%-8.48%+9.26% 5.79B
Weighted average by Cap. -2.56%-3.77%-31.90%+38.92%

Financials

2026 *2027 *
Net sales 81.87M 71.77M 66.69M 61.24M 115M 7.91B 117M 793M 310M 3.86B 307M 301M 13.35B 86.26M 75.61M 70.26M 64.52M 121M 8.33B 123M 836M 327M 4.07B 324M 317M 14.07B
Net income 9.53M 8.36M 7.77M 7.13M 13.43M 921M 13.64M 92.36M 36.13M 450M 35.78M 35.02M 1.55B 10.18M 8.92M 8.29M 7.62M 14.34M 983M 14.57M 98.64M 38.58M 480M 38.21M 37.39M 1.66B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
26-07-22 US$18.25 +0.11% 1,066,053
26-07-21 US$18.23 +0.11% 2,071,404
26-07-20 US$18.21 -0.11% 504,896
26-07-17 US$18.23 0.00% 251,752
26-07-16 US$18.23 -0.11% 371,791
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.25USD
Average target price
17.25USD
Spread / Average Target
-5.48%

Quarterly revenue - Rate of surprise